Symbols

CBIO

Crescent·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CBIO

Crescent Biopharma, Inc.

A biotechnology company focusing on the development of new anti-tumor drugs

Industry

Biological Technology

Established Date

Listing Date

01/10/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.crescentbiopharma.com

Security Type

Common stock

Office address

300 Fifth Avenue Waltham MA 02451

Business

Introduction

Crescent Biopharma, Inc., was incorporated in Delaware in 2003, and the company's place of incorporation was changed from Delaware to the Cayman Islands on June 16, 2025. The company is a clinical-stage biotechnology company focused on delivering transformative therapies to cancer patients. Crescent Biopharma aims to become a leading oncology biotechnology company through two major strategies: first, the development of CR-001, a PD-1 x VEGF bispecific antibody designed to simultaneously target PD-1 immune checkpoint and vascular endothelial growth factor (VEGF), which is expected to replace pembrolizumab as the underlying therapeutic drug; and second, the construction of a powerful antibody-drug conjugate (ADC) product portfolio. The company plans to use CR-001 in combination with ADC therapy to form a synergistic combination therapy with the goal of improving the treatment of multiple cancers. The global Phase 1/2 trial of CR-001 (i.e. ASCEND trial) was launched in February 2026, and further clinical trials of CR-002 and CR-003 are expected to start in the same year.

Company Financials

EPS

CBIO has released its 2025 Q4 earnings. EPS was reported at -3.35, versus the expected -2.47, missing expectations. The chart below visualizes how CBIO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CBIO has released its 2025 Q4 earnings report, with revenue of 10.84M, reflecting a YoY change of NaN%, and net profit of -92.40M, showing a YoY change of -506.44%. The Sankey diagram below clearly presents CBIO's revenue sources and cost distribution.